Printer Friendly

FDA Approves New Bausch & Lomb Eye Surgery Device For U.S. Sale.

Business Editors

-- Innovative Technology Is Breakthrough for Vitreoretinal Microsurgery

-- 25-Gauge Entry Site Alignment (ESA) Device Allows For Smaller Incisions

The U.S. Food and Drug Administration has cleared Bausch & Lomb's 510(k) application allowing the company to sell its innovative 25-Gauge Entry Site Alignment (ESA) device in the United States.

A patent is pending on this key component of the Bausch & Lomb Millennium(TM) TSV25 System for Transconjunctival Standard Vitrectomy, which is expected to be available starting in December.

The Bausch & Lomb system represents a technology breakthrough in surgery involving the back - or posterior segment - of the eye. The surgical technique, called vitrectomy, is used to correct visually devastating conditions including retinal detachments, macular degeneration, and diabetic eye diseases. Each year, surgeons perform an estimated 200,000 vitrectomies in the United States, and about 500,000 worldwide.

With Bausch & Lomb's Millennium TSV25 System, surgeons can make micro incisions that are approximately one half the size of standard incisions. The result is less trauma to the eye. The Bausch & Lomb Millennium TSV25 System is the only system this size available on the market.

Eugene de Juan, Jr., M.D., CEO of The Retina Institute at the Doheny Eye Institute of the University of Southern California at Los Angeles, says, "The 25-Gauge Entry Site Alignment and vitrectomy system, when used transconjunctivally, greatly facilitates the ease and speed of common vitreoretinal procedures. I expect this system to be quickly and widely used as part of our vitreoretinal armamentarium."

The Bausch & Lomb Millennium TSV25 System "moves us one step closer to performing micro surgery in office-based clinical settings," according to John Saharek, Bausch & Lomb marketing director for vitreoretinal products. "We see trends that these types of surgical procedures will be moving away from hospitals to office-based surgical suites. Doing so may lead to increased patient acceptance, convenience and access to care and also help to lower the overhead and personnel costs associated with these procedures."

Bausch & Lomb Incorporated is the preeminent global technology-based healthcare company for the eye, dedicated to helping consumers see, look and feel better through innovative technology and design. Its core businesses include soft and rigid gas permeable contact lenses, lens care products, ophthalmic surgical and pharmaceutical products. The company is advantaged with some of the most respected brands in the world starting with its name, Bausch & Lomb(R), and including SofLens(TM), PureVision(TM), Boston(R), ReNu(R), Storz(R) and Technolas(TM). Founded in 1853 in Rochester, N.Y., where it continues to have its headquarters, the company has annual revenues of approximately $1.8 billion and employs approximately 12,000 people in more than 50 countries. Bausch & Lomb products are available in more than 100 countries around the world. Additional information about the company can be found on Bausch & Lomb's Worldwide Web site at
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 29, 2001
Previous Article:ADVISORY/Experts Available to Discuss Low-Impact Exercise and Bone Mass Gain.
Next Article:HickoryTech Reschedules Quarterly Conference Call; Third Quarter Earnings Release to be Issued After Market Close Today.

Related Articles
Bausch & Lomb Provides Additional Information to FDA in Response to Warning Letter Regarding Advertising and Promotion for PureVision-tm-.
Bausch & Lomb's Newest Intraocular Lens for Cataract Surgery, Hydroview, Receives Regulatory Approval in Japan.
Bausch & Lomb Introduces Zyoptix; Personalized Laser Vision Correction Solutions.
Seeing The Future.
FDA Accepts Bausch & Lomb Modular Premarket Approval Application for its Zyoptix System for Customized LASIK Vision Correction.
Bausch & Lomb Technolas 217A Excimer Laser System Now FDA Approved to Treat Hyperopia with Astigmatism.
Bausch & Lomb Previews New Single-Use IOL Insertion System at American Society for Cataract and Refractive Surgery Meeting.
FDA Approves Bausch & Lomb's Patented Retisert Orphan Drug.
Diabetic Macular Edema trial with Retisert(TM); Positive Results for pSivida.
Lawyers focus on lens solution lawsuits.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters